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 In contrast to the progress that has been made towards understanding the genetic 
etiology of cleft lip with or without cleft palate (CL/P), relatively little is known about the genetic 
etiology for cleft palate only (CPO). Recently, a common coding variant of Grainyhead Like 
Transcription Factor 3 (GRHL3) was shown to be associated with risk for CPO in Europeans. 
Mutations in this gene had also been previously reported in families with Van der Woude 
syndrome (VWS). To identify rare mutations in GRHL3 that might explain the missing heritability 
for CPO, we sequenced GRHL3 in cases with CPO from Africa. We recruited participants from 
Ghana, Ethiopia and Nigeria. This cohort included case-parent trios, cases and other family 
members, as well as controls. In total we sequenced exons of this gene in DNA from 134 non-
syndromic cases. When possible, we sequenced them in parents to identify de novo mutations. 
Five novel mutations were identified including two missense (c.497C>A; p.Pro166His and 
c.1229A>G; p.Asp410Gly), a splice site (c.1282A>C p.Ser428Arg), a frameshift (c.470delC; 
p.Gly158Alafster55), and a nonsense mutation (c.1677C>A; p.Tyr559Ter)). These mutations 
were absent from 270 sequenced controls and from all public exome and whole genome 
databases, including the 1000 genomes database (which includes data from Africa). However, 
four of the five mutations were present in unaffected mothers, indicating that their penetrance is 
incomplete. Interestingly, one mutation damaged a predicted sumoylation site, and another 
disrupted a predicted CK1 phosphorylation site. Over-expression assays in zebrafish and 
reporter assays in vitro indicated that four variants were functionally null or hypomorphic while 
one was dominant-negative. This study provides evidence that, as in Caucasian populations, 
mutations in GRHL3 contribute to the risk of non-syndromic CPO in the African population.  
 





 Orofacial clefts (OFC) are common in humans and are the most common craniofacial 
birth defects, with a worldwide prevalence of 1 in 700 live births (Mossey and Little 2002). They 
are usually divided into syndromic and non-syndromic clefts. Non-syndromic clefts, which 
account for about 70% of all clefts, occur without additional visible clinical features.  Syndromic 
clefts are associated with additional structural abnormalities. The cleft spectrum that includes 
cleft palate only (CPO), cleft lip only (CLO) and cleft lip with or without palate (CL/P) can be 
found in either syndromic or non-syndromic clefts. About 50% of CPO is classified as syndromic 
clefts (Marazita et al. 2002).  Regardless of the category or types of clefts, the rehabilitation of 
affected individuals requires a multidisciplinary team approach. For instance, in the U.S., it has 
been estimated that the lifetime cost of managing a child with cleft may total as much as 
$100,000 (Waitzman et al., 1994). Therefore, OFCs places a huge personal and financial 
burden on families, society and healthcare systems, particularly in developing countries where 
social and physical infrastructures are limited. 
 The etiology of non-syndromic cleft palate is complex and factors including genetics, 
environmental exposures and gene-environment interaction are plausible causes (Beaty et al., 
2016). Unlike nonsyndromic CL/P where over 26 risk loci and several candidate genes have been 
implicated through some genome-wide association studies (GWAS) (Beaty et al., 2010; Ludwig 
et al., 2012; Sun et al., 2015; Leslie et al., 2016a; Leslie et al.,2017; Yu et al.,2017), little is 
known about the genetic causes of CPO. Ghassibe et al in 2011 reported a role for FAS-
associated factor 1 (FAF1) in CPO when they demonstrated that haploinsufficency of FAF1 
causes CPO in a family with Pierre Robin Sequence (PRS) (Ghassibe et al. 2011). Pierre Robin 
Sequence is characterized by CPO, micrognathia and glossoptosis. In another study, Kilpatrick 
et al. in 2003 reported two de novo CPO-associated translocations involving 2q32-q33 where 
one breakpoint obstructs the transcription unit of Special AT-rich sequence-binding protein 2 
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(SATB2) (Kilpatrick et al. 2003).  Also, mutations in T-Box 22 (TBX22) have been reported in X-
linked CPO cases (Braybrook et al. 2001; Braybrook et al. 2002; Marcano et al. 2004). 
 Two recent independent studies identified a common missense mutation, p.Thr454Met, 
in GRHL3 that is associated with CPO (Leslie et al. 2016b; Mangold et al. 2016). The first was a 
case-control/case-triad GWAS (Leslie et al., 2016b); and the second was a combination of 
targeted sequencing and association study (Mangold et al. 2016). Mutations in GRHL3 have 
been previously reported in VWS cases with CPO (Peyrard-Janvid et al. 2014). GRHL3 
encodes the transcription factor Grainyhead-like 3, which is necessary for formation of the 
epidermal permeability barrier in mice (Ting et al. 2005). Both it and the transcription factor 
Interferon Regulatory Factor 6 (IRF6) are necessary for differentiation of oral periderm, the most 
superficial layer of oral epithelium that covers palate shelves during morphogenesis of the face 
(Peyrard-Janvid et al. 2014; Ingraham et al. 2006).  Loss of oral periderm results in adhesions 
between palate shelves in mice (Richardson et al. 2009); leading to the proposal that defective 
differentiation of oral periderm is the cellular event that ultimately results in cleft palate.  In 
zebrafish, two homologues of GRHL3; Grhl1 and Grhl3, acting redundantly and the ortholog of 
IRF6 are required for differentiation of periderm, the most superficial layer of embryonic skin, 
with the Grhl factors  acting as a downstream of Irf6 (Sabel et al. 2009; de la Garza et al. 2013). 
Injection of RNA encoding human GRHL3 mRNA into zebrafish eggs induced ectopic 
expression of a keratin 4 (krt4), a marker of the periderm, in deep blastomeres at gastrula stage 
(de la Garza et al. 2013); this assay was used to show that VWS-associated and non-syndromic 
CPO-associated variants of GRHL3 lack normal function (Peyard et al. 2014; Leslie et al., 
2016b). In both cases, disease-associated variants disrupted differentiation of periderm in wild-
type embryos, indicating they had dominant-negative activity. 
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 Importantly, the common variant p.Thr454Met in GRHL3 explains only a fraction of the 
heritability for CPO. To identify rare variants that could explain in part the heritability for CPO, 
we conducted targeted sequencing of GRHL3 gene in individuals with CPO from Ghana, 
Ethiopia and Nigeria. We tested novel variants found in patients in functional assays in cell lines 
and in zebrafish embryos. 
 
Subjects and Methods  
 This study is part of a collaborative study that investigates the genetic and environmental 
causes of orofacial clefts in sub-Saharan Africans from Ghana, Ethiopia and Nigeria. Local 
Institutional Review Boards (IRBs) approved sample and data collection: Ethiopia-Institutional 
Review Board College of Health Sciences, Addis Ababa University IRB No 3.10/027/2015; 
Kwame Nkrumah University of Science and Technology, Kumasi, Ghana– IRB No 
CHRPE/AP/217/13; and College of Medicine University of Lagos, Nigeria – IRB No 
ADM/DCST/HREC/APP/1374. Patients born with cleft palate only, controls and parents of both 
cases and controls were recruited and assessed at treatment centers in each country by the 
investigators and their collaborators. Informed consent was obtained from all participating 
families and saliva samples were collected using Oragene saliva kits and sponges (DNA 
Genotek, Kanata, ON, Canada). These samples were sent to the Butali Laboratory at the 
University of Iowa, USA, for processing and analysis. We extracted DNA from all samples 
followed by XY genotyping analysis to ensure the gender of the sample matched the gender of 
the donor, and for quality control purposes. A combination of 134 case-parent samples (dyads 
and triads), as well as 270 unrelated controls (90 from each of the three countries), were 





 For sequencing DNA from human subjects we used methods that we reported previously 
(Gowans et al. 2016). We used primers that were optimized for the amplification of 17 exons in 
the GRHL3 gene (NM_198174). We used 4 ng of DNA in a 10 ul reaction for the Polymerase 
chain reaction (PCR). Two Yoruba HapMap samples and two water samples were added to the 
96 well plates as template and non-template controls, respectively. The primers used and 
annealing temperatures are available from the Butali Laboratory upon request. The amplified 
DNA products were sequenced at Functional Biosciences 
(http://order.functionalbio.com/seq/index) (Madison, WI).  
 To recognize novel mutations, we compared mutations that we identified in patients with 
those in the 1000 genomes (1KG) database (http://www.1000genomes.org/), Exome variant 
sequence (EVS) database (http://snp.gs.washington.edu/EVS/), and Exome Aggregate 
Consortium (ExAC) database (http://exac.broadinstitute.org/). These databases included exome 
data for over 5200 African and African American controls. We also sequenced 270 controls as 
an additional step to confirm novel mutations. To predict the functional effects of novel 
mutations on the protein, we used bioinformatics tools such as Polymorphism Phenotyping 
(Polyphen) (http://genetics.bwh.harvard.edu/pph2/) (Adzhubei et al. 2010), Sorting Intolerant 
From Tolerant (SIFT) (http://sift.jcvi.org/) (Kumar et al. 2009), and Have Your Protein Explained 
(HOPE) (http://www.cmbi.ru.nl/hope) (Venselaar et al. 2010).  To assess inheritance of novel 






Functional test of human GRHL3 mutations in zebrafish embryos 
 Full-length, wild type human GRHL3 cDNA (GenBank: BC036890.2) was obtained from 
GE Healthcare (Pittsburgh, PA). Novel GRHL3 mutations were introduced into the wild type 
using PCR-mediated mutagenesis and the cDNAs shuttled into CS2+ vector (gift of David 
Turner, University of Michigan). The corresponding capped mRNAs were generated in vitro with 
the mMESSAGE mMACHINE SP6 kit (Ambion, Grand Island, NY) and purified with the RNeasy 
mini kit (Qiagen, Valencia, CA). For “rescue” experiment, 5 nl of grhl1 AUG MO and/or of grhl3 
E4I4 MO, each at 1 mg/ml, were injected into wild-type zebrafish embryos (NHGRI line) at the 
single cell stage after which approximately 1 ng different human GRHL3 mRNAs were injected 
into the same embryos.  Embryos were fixed at 8 hours post fertilization (hpf) and whole-mount 
in situ hybridization for krt4 was performed as described previously (Sabel et al., 2009). For 
cryo-section, after in situ hybridization embryos were embedded in Tissue-Tek® O.C.T. 
Compound (Sakura Finetek, USA) at -80°C. 10 micron sections were made using Microm 
Cryostat I HM505E (GMI, Ramsey, MN).  The Public Health Service Assurance approved 
animal use protocols (protocol No. 6011616). Details of RNA extraction and luciferase assay are 
included in Appendix. 
 
 
Results     
Novel GRHL3 mutations detected in patients with cleft palate only 
 We sequenced GRHL3 exons and splice sites in 134 cases with non-syndromic CPO 
and none in 270 controls. We identified five novel variants in patients that were absent from 
controls, from the ExAc database of more than 100,000 whole exomes, and the 1000 Genomes 
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database of whole genome sequences (accessed on 08/04/2017). The mutations included 2 
missense (p.Pro166His and p.Asp410Gly, referring to GRHL3 isoform 2, NP_937816), one 
splice site (p.Ser428Arg), a deletion (p.Gly158Alafster55), and one nonsense mutation 
(p.Tyr559Ter) (Table 1, Fig. 1A). All of the identified mutations except for p.Ser428Arg were 
also detected in an unaffected parent.  For the p.Ser428Arg mutation, we only have samples for 
the mother who did not have the mutation (Table 2). We also identified known missense 
mutations in cases (Appendix Table 1). The five novel variants have been deposited into the 
Leiden Open Variation Database with submission number 00100262. 
 
CPO patient-derived variants of GRHL3 have lower-than-normal ability to induce ectopic 
expression of a periderm marker in zebrafish embryos. 
 We first tested the activity of CPO-patient derived GRHL3 variants in an over-expression 
paradigm.  We engineered each of variants into full length GRHL3 cDNA, synthesized mRNAs 
in vitro, and injected the mRNAs (or lacZ mRNA as a negative control) singly into single-cell 
zebrafish embryos, fixed embryos at 6 hours post-fertilization (hpf)(shield stage), and processed 
them to reveal krt4 expression by in situ hybridization (Peyard-Janvid et al. 2014; Leslie et al. 
2016b). All embryos injected lacZ mRNA exhibited krt4 expression solely in the enveloping layer 
(EVL), which is the normal pattern of expression (40 of 40 embryos injected) (Rauch et al. 2003) 
(Fig. 1B; Appendix Fig.1). In contrast, all embryos injected with wild-type human GRHL3 mRNA 
exhibited large patches of ectopic expression of krt4 in deep blastomeres readily visible in a 
whole-mount preparation (Fig. 1C) and confirmed by in sectioned embryos (Appendix Fig. 1) (40 
of 40 injected embryos). In embryos injected with the p.Gly158Alafster55 (Fig. 1D), 
p.Asp410Gly (Fig. 1F) and p.Ser428Arg (Fig. 1G) variants there were no ectopic patches of krt4 
expression (more than 60 embryos for each construct).   In contrast, a small fraction (<10%) of 
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embryos injected with the p.Pro166His (Fig. 1E) and p.Tyr559Ter (Fig. 1H) variants exhibited 
small patches of ectopic krt4 expression (4 of 88, and 5 of 91 embryos injected, respectively), 
revealing that in this assay these variants are hypomorphic (i.e., less active than wild-type). 
Moreover, in about half of embryos injected with the p.Ser428Arg variant, there were clear gaps 
in the expression of krt4 (23 of 64 embryos injected and processed for krt4 expression) (Fig. 
1G); one of the embryos injected with this construct ruptured just prior to fixation (i.e., at 8 hpf). 
Therefore we repeated the experiment with this variant and permitted embryos to continue to 
develop. By 9 hpf, 36 of 83 embryos injected had ruptured similar to embryos injected with a 
dominant-negative variant of Grhl3 (de la Garza et al. 2009). In summary, the results indicate 
that in the over expression assay, the p.Pro166His and p.Tyr559Ter variants are hypomorphic, 
p.Gly158Alafster55 and p.Asp410Gly variants are strongly hypomorphic or null, and the 
p.Ser428Arg variant is dominant-negative.   
 
Next, in a rescue paradigm, we asked whether krt4 expression could be restored by injection of 
mRNA encoding GRHL3 variants. Previously we showed that simultaneous inhibition of grhl1 
and grhl3 using morpholinos disrupts epiboly and krt4 expression, but knockdown either of gene 
singly does are not grossly affect periderm development (de la Garza, et al. 2009) (Fig. 2A-D). 
For rescue assays, we injected human GRHL3 variants into embryos depleted of both grhl1 and 
grhl3. Injection of wild-type GRHL3 into embryos injected with grhl1 MO and grhl3 MO partially 
restored superficial krt4 expression and induced ectopic expression of krt4 in deep blastomeres 
(Fig.2 E). For quantitative comparisons of rescue efficiency, we evaluated krt4 expression in 
whole embryo lysates by qRT-PCR (Fig. 2F).  Embryos injected with grhl1 MO and grhl3 MO 
(i.e., double morphants) injected with LACZ mRNA had significantly lower krt4 expression than 
those injected control morpholino, whereas double-morphants injected with RNA coding the 
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reference (wild type) variant, the p.Pro166His variant, or the p.Tyr559Ter variant of GRHL3 had 
significantly higher levels of krt4 expression than those injected with LACZ mRNA. krt4 
expression levels in double morphants injected with the other variants (p.Gly158Alafster55, 
p.Asp410Gly and p.Ser428Arg) were not significantly higher than those in embryos injected with 
LACZ, and were significantly lower than in those injected with wild-type GRHL3 (p<0.01 by one-
way ANOVA) (Fig. 2F). 
 
CPO patient-derived variants have lower-than-normal ability to activate a GRHL3 
sensitive reporter  
 We next assessed the ability of the GRHL3 variants to activate a synthetic GRHL3-
sensitive reporter, which was comprised of 6 GRHL3 binding sites upstream of a minimal 
promoter and the firefly luciferase gene (Leslie et al. 2016b). We co-transfected 293FT cells 
with the GRHL3-sensitive reporter, expression vectors harboring different GRHL3 variants 
(separately), and a plasmid driving constitutive Renilla luciferase expression as a transfection 
control (internal control). As controls, we additionally tested other patient-derived GRHL3 
variants, both previously shown to have dominant-negative activity in zebrafish: p.Arg391Cys, 
from an individual with VWS (Peyard-Janvid et al. 2014) and p.Thr454Met, a common variant 
associated with risk for nsCPO (Leslie et al., 2016b Mangold et al., 2016). Compared to cells 
transfected with the GRHL3-sensitive reporter alone, those additionally transfected with the 
expression vector containing wild-type GRHL3 had more than 6-fold greater luciferase levels 
(Fig. 3).  By contrast, expression vectors containing the p.Ser428Arg did not activate the 
reporter above background, and those containing p.Pro166His, p.Tyr559Ter and p.Thr454Met 
variants did so but to a significantly lesser level than did wild-type (Fig. 3A). Of note, the 
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p.Pro166His and p.Tyr559Ter were the variants that also retained some ability to induce ectopic 
krt4 expression in zebrafish embryos (Fig. 1E,H). 
 
p.Ser428Arg GRHL3 variant shows dominant negative effects in 293FT cells. 
 Finally, to test the patient-derived GRHL3 variants for dominant-negative activity, we co-
transfected equal amounts of expression vectors containing wild-type and a patient-derived 
variant. The p.Ser428Arg, p.Arg345Cys and p.Thr408Met, which all had dominant-negative 
activity in the zebrafish assay, also all decreased the reporter levels compared to cells 
transfected with wild-type GRHL3 alone (Fig. 3B). The remaining variants all had additive 
effects when combined with wild-type GRHL3, indicating they are loss-of-function but not 
dominant-negative variants.  In summary, variants of GRHL3 detected in patients with CPO all 
had reduced function in comparison to the reference variant, and a subset had dominant-
negative activity, consistent with their having pathogenic effects. 
 
Discussion 
 Based on evidence on the association of a variant of GRHL3 with CPO in Europeans, 
we tested the hypothesis that rare-function blocking variants of GRHL3 contribute to 
pathogenesis of NS CPO in Sub Saharan Africa by sequencing the GRHL3 exons in such 
patients. We detected 5 variants that were of interest because of their absence from public 
domain catalogs of coding variants and because one or more in silico algorithm predicted they 
were “possibly damaging” or worse. We subjected all of them to functional assays in zebrafish, 
including an over-expression and a rescue of grhl3 loss-of-function paradigm, and to in vitro 
tests of their transactivation activity, all in comparison to the reference variant of GRHL3. These 
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assays consistently indicated that two variants, p.Pro166H and p.Tyr559Ter, were modestly 
hypomorphic, two others, p.Gly158Alafster55 and p.Asp410Gly, were strongly hypomorphic or 
null, and one, p.Ser428Arg, was dominant negative.  These findings raise several issues as 
follows. 
 
 First, the presence of some of these mutations in unaffected family members suggests 
that their effects are completely penetrant, as has been reported in previous genetic studies of 
clefting (Mangold et al. 2016). Modifier alleles in the parents may be protective for clefting but 
simultaneously elevate their risk for other chronic diseases like cancer which has elevated 
prevalence in families with clefts (Christensen et al. 2004; Bille et al. 2005). Alternatively, 
affected children and unaffected parents may share the same genetic risk factors but may have 
been differentially exposed to environmental factors, such as maternal smoking during the 
periconceptional period, leading to clefts in the presence of risks alleles (Little et al. 2004).   
 
 Second, it is noteworthy that our functional assays had only modest concordance with in 
silico algorithms that predict the functional consequence of missense variants, e.g., Polyphen, 
SIFT, and HOPE.  The most extreme disagreement was for the p.Ser428Arg variant, which had 
dominant-negative activity in our assays, but was predicted to be benign by both Polyphen and 
SIFT. The p. Pro166His mutation, which had hypomorphic activity in our in vivo and in vitro 
assays, was predicted to be “probably damaging” by Polyphen and “tolerated” by SIFT with a 
Provean score of -0.64. The p.Tyr559Ter variant, which had reduced transactivation activity in 
our in vitro assay, was predicted to be a gain of function mutation by HOPE leading to increased 
activity of GRHL3.  The p.Asp410Gly variant, which in our assays was loss-of-function, 
Polyphen predicted to be probably damaging and SIFT predicted to be deleterious. The strength 
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of the zebrafish-based assays is that they tested the variants function in the context of a gene 
regulatory network governing differentiation of a relevant tissue.   The in vitro assays have the 
advantage of being more quantitative than the in vivo ones.  The results from in vivo assay is 
consistent with the two in vitro assays, which agreed with one another, all supporting their 
validity. Functional assays remain an important complement to in silico algorithms for discerning 
pathological variants from innocuous ones. 
 
 Third, the specific biochemical deficits in each functional variant are unknown and are an 
interesting subject for future study. One or more of the variants may diminish the protein’s 
stability which is testable with appropriate antibodies or epitope-tagged variants. HOPE 
predicted that p.Ser428Arg disrupts a potential phosphorylation site of the kinase CK1, although 
it is unknown if GRHL3 is phosphorylated at this residue. The same algorithm predicted that the 
substitution of proline by histidine in the p.Pro166His variant will lead to a loss of hydrophobic 
interaction in the nucleus or surface of the protein, and prolines provide rigidity to local protein 
conformation. Finally, it predicted that p.Asp410Gly disrupts a potential sumoylation site; 
sumoylation of lysine residues generally alters protein stability, function, or subcellular 
localization (Hendrik and Vertegaal 2015). It remains to be determined if this residue of GRHL3 
is subjected to sumoylation.  
 
Conclusion 
 We identified novel GRHL3 variants in CPO patients and tested them in functional 
assays that had the ability to recognize wild-type, reduction in function, and dominant-negative 
activities.  The results of the functional tests suggest that lower-than-normal levels of GRHL3 
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and not necessarily dominant negative, activity can confer increased susceptibility to CPO. The 
p.Thr454Met variant, first identified in a European GWAS was not found in our samples, but 
other rare variants of GRHL3 influence heritability for CPO in Africans.  These findings expand 
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Table 1 Sequence variations for GRHL3 observed in CPO individuals from sub-Saharan 
Africa 
HGVS HGVp Type Ghana Nigeria 1KG EVS ExAC p S PS 
c.332delC p.Gly158Alafster55 Frameshift 
0 1 0 0 0    
c.497C>A p.Pro166His Missense 





0 1 0 0 0 PD D -6.7 
c.1282A>C p.Ser428Arg Missense 
0 1 0 0 0 B T -1.46 
c.1677C>A p.Tyr559Ter Stop-gain 
1 0 0 0 0    
1Kg= 1000 Genomes, EVS= Exome Variant Server, ExAC= Exome Aggregate Consortium 
P=Polyphen, S=SIFT, PS= Provean Score, B= Benign, T= Tolerated, PD= probably damaging, 
D= Deleterious. c. refers to coding sequence position within the GRHL3 transcript NM_198173, 







































Table 2: Segregation analyses of novel mutations in case families 
HGVS HGVp Individual  Genotypes 
c.497C>A p.Pro166His case child CA 
c.497C>A p.Pro166His mother CA 
c.497C>A  p.Pro166His grandmother CA 
    c.1677C>A p.Tyr559Ter case child CA 
c.1677C>A p.Tyr559Ter Father CA 
c.1677C>A p.Tyr559Ter mother CC 
    c.1229A>G p.Asp410Gly case child AG 
c.1229A>G p.Asp410Gly mother AG 
    c.1282A>C p.Ser428Arg case child AC 
c.1282A>C p.Ser428Arg mother AA 
    c.470delC p.Gly158Alafster55 case child C- 














Figure 1. Rare variants in GRHL3 disrupt development of zebrafish EVL upon 
overexpression in zebrafish embryos. A) Schematic of the GRHL3 gene and the position of 
mutations identified in the present (red arrows) and previous studies (black arrows) (not to 
scale). All amino acid positions refer to GRHL3, variant 2 (NP_937816).  The green arrow 
represents the missense mutation p.Thr454Met that is a common variant associated with non-
syndromic CPO reported by Leslie et al., 2016 and Mangold et al., 2016. The yellow bar 
represents the DNA binding domain where the sumoylation and CK1 phosphorylation motifs are 
harbored in exon 4. The purple bar represents the dimerization region while the green bar 
represents the transcription activation domain. Blue boxes represent exons. B-H) Animal pole 
views of embryos fixed at 7 hpf and processed to reveal krt4 expression. B) Embryos injected 
with lacZ mRNA, a negative control, have relatively even expression of krt4 in all enveloping 
layer (EVL) cells (in three biological replicates of at least 40 injected embryos each, all had this 
appearance. None exhibited expression of krt4 in deep blastomeres). C) Embryos injected with 
mRNA encoding a reference variant of human GRHL3 (AAH36890.1) develop with intense foci 
of krt4 expression in deep blastomeres, recognizable in whole mount preparations as patches of 
dark staining (e.g., red asterisk) (in three separate experiments of at least 40 injected embryos 
each, all exhibited patches of ectopic krt4 expression). D, F) Embryos injected with mRNA 
encoding the reference variant above altered to have the patient variants D) p.Gly158Alafster55 
or F) p.Asp410Gly lacked ectopic patches of krt4 expression, consistent with these being 
hypomorphic variants. Although krt4 expression intensity appears lower than normal in this 
image, this was not consistently observed (in three biological replicates, a total of 99 total 
embryos injected, none exhibited patches of ectopic krt4 expression. 10 or fewer non-
contiguous deep cells expressing krt4 in deep cells were observed in fewer than half of injected 
embryos). E,H) Rare embryos injected with E) p.Pro166His and H) p.Tyr559Ter variants 
exhibited patches of ectopic krt4 expression (stars), indicating these variants retained activity 
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but at lower than wild-type levels (in three experiments, 4 of 88 and 5 of 91 injected embryos, 
respectively, exhibited patches of ectopic krt4 expression as shown). G) About one third of 
embryos injected with p.Ser428Arg variant exhibited gaps in the expression of krt4 (in three 
experiments, 23 of 64 injected embryos showed such gaps). Fractions: numerator is the number 
of embryos resembling the one in the image; denominator is the number of embryos injected. 
The residue in each case resembles un-injected embryos. 
 
Figure 2. Injection of human GRHL3 RNA partially restored krt4 in the embryos injected 
with grhl1 and grhl3 MOs. A-E) Animal pole views of embryos fixed with the injected reagents 
at the one-cell stage, fixed at 6 hpf and processed to reveal krt4 expression by in-situ 
hybridization. In embryos injected with A) control MO, B) grhl1 MO, or C) grhl3 MO, krt4 
expression is contiguous, whereas in embryos injected with D) both grhl1 MO and grhl3 MO krt4 
expression is highly reduced. E) In embryos injected with grhl1 MO and grhl3 MO and also with 
human GHRL3 mRNA, there was mosaic rescue of krt4 expression in the EVL, in addition to 
ectopic krt4 expression in the deep layer cells.  Fractions: numerator is number of embryos 
resembling the injected one (in E, includes ectopic krt4-expressing cells), denominator is the 
total number of embryo injected.  In D, the residual embryos resembled control MO-injected 
ones. In E, the residual embryos resembled those injected grhl1 MO and grhl3 MO pictured in D. 
F qRT-PCR analysis of krt4 mRNA levels in embryos injected with the indicated MO and 
indicated mRNA. **, significant (p<0.01) in comparisons to the “grhl1 MO+grhl3 MO+lacZ” group 





Figure 3. In vitro reporter analysis of transactivation activity of rare variants in GRHL3. A) 
Bar chart representing firefly luciferase activity, normalized to Renilla luciferase activity, in 
293FT cells co-transfected with the indicated (0.5 µg) GRHL3 expression constructs, or pCS2+ 
plasmid, together with 0.5 µg of a GRHL3-sensitive firefly reporter plasmid and 0.05 ug a 
constitutive Renilla reporter plasmid as a transfection control. B) Bar chart representing firefly 
luciferase activity, normalized to Renilla luciferase activity, in 293FT cells co-transfected with 0.5 
µg indicated GRHL3 expression constructs (or CS2+) along with 0.5 µg wildtype GRHL3 
expression constructs, the GRHL3-sensitive firefly reporter plasmid, and the Renilla reporter 
plasmids. p.Arg345Cys is a rare GRHL3 variant found in Van der Woude syndrome (referred to 
as p.Arg391Cys in Peyrard-Janvid et al., 2014), and p.Thr408Met is the CP-associated GRHL3 
variants reported previously (referred to as pThr454Met in Leslie et al., 2016, Mangold et al., 
2016). These two variants serve as positive controls for dominant negative activity for the 
current study. The data represent results from three separate experiments, and error bars 
represent standard error. Asterisk indicates p < 0.05. 
 
 
